

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31902C3	PRED. SERIAL NO. 10/154,725
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Buckingham et al.	
		PRED. FILING DATE May 24, 2002	PRED. GROUP ART UNIT 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
EW	5,002,953	3/26/91	Hindley	514	275	
	6,288,095	9/11/01	Hindley et al.	514	367	
	20020006939	1/17/02	Buckingham et al.	514	340	
	5,194,443	3/16/93	Hindley	514	367	
	5,232,925	8/3/93	Hindley	514	272	
	5,260,445	11/9/93	Hindley	548	183	
	5,521,201	5/28/96	Hindley et al.	514	342	
	5,646,169	7/8/97	Hindley et al.	514	369	
	5,741,803	4/21/98	Pool et al.	514	342	
	5,756,525	5/26/98	Hindley et al.	514	364	
	5,910,592	6/8/99	Pool et al.	546	269.7	
	6,166,049	12/26/00	S.A. Smith	514	352	
	5,972,944	10/26/99	Antonucci et al.	514	252	
	20030069283	4/10/03	Buckingham et al.	514	342	
	20030109552	6/12/03	R.E. Buckingham	514	342	
EW	20020049240	4/25/02	Hindley et al.	514	369	

## FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
EW	WO 00/27341	5/18/00	PCT				
	WO 98/55122	12/10/98	PCT				
	WO 98/02159	1/22/98	PCT				
	WO 97/05875	2/20/97	PCT				
	WO 97/18811	5/29/97	PCT				
	0 796 618	9/24/97	EP				
	0 419 035	3/27/91	EP				
	0 419 035 B1	2/15/95	EP				
	WO 94/25026	11/10/94	PCT				
	WO 95/07694	3/23/95	PCT				
EW	WO 97/25042	7/17/97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

IC	"R&D Focus Drug News", Dialog File Supplier: File 445 R&D Focus, Accession Numbers 16402 and 14818, 05 May 1997 – 10 March 1997. XP002082979.
IC	"Rosiglitazone SmithKline Beecham Clinical Data", STN File Supplier: Drugnl: Accession Number 1391 & R&D Focus News, 27 April 1998, XP002082989.
EXAMINER	DATE CONSIDERED
NO - WHEE	16-3104

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31902C3	PRED. SERIAL NO. 10/154,725
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Buckingham et al.	
		PRED. FILING DATE May 24, 2002	PRED. GROUP ART UNIT 1614

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Re	5,478,852	12/1995	Olefsky et al.	514	369	

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes   No
WO 94/05659	3/1994	PCT			
0 306 228 A1	3/1989	EP			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

IC	"The Pink Sheet", Dialog File Supplier: File 187: F-D-C Reports, Accession Number 600160005, Vol. 60(16), 20 April 1998. XP002082978.
	"Physician's Desk Reference 54th Edition, 2000, Medical Economics Company, pages 2980-2984, citation based on labeling dated June 15, 1999.
	National Institute for Clinical Excellence, Appraisal Consultation Document, D. Barnett, Review: "The Clinical Effectiveness and Cost Effectiveness of Glitazones for the Treatment of Type 2 Diabetes", January 2003.
	Kumar et al. "Troglitazone, an Insulin Action Enhancer, Improves Metabolic Control in NIDMM Patients". <i>Diabetologia</i> , 39(6): 701-709 (1996).
	Berger et al., "Thiazolidinediones Produce a Conformational Change in Peroxisomal Proliferator-Activated Receptor Gamma: Binding and Activation Correlate with Antidiabetic Actions in db/db Mice". <i>Endocrinology</i> , 137(10): 4189-4195 (1996).
	Florez et al., "Pasos hacia la prevencion primaria de la diabetes mellitus tipo II. Algunas consideraciones epidemiologicas". <i>Invest. Clin.</i> , 38(1): 39-52.
	Grossman et al., "Mechanisms and Clinical Effects of Thiazolidinediones". <i>Expert Opin. Invest. Drug</i> , 6(8): 1025-1040 (1997). (Abstract)
	Chang et al., "The Hypoglycemic effect of Ciglitazone in Obese, Hyperglycemic Animal Models". <i>Prog. Clin. Biol. Res.</i> , 265: 177-192 (1988) (Abstract).
	Stevenson et al., "Actions of Novel Antidiabetic Agent Englitazone in Hyperglycemic Hyperinsulinemic ob/ob Mice". <i>Diabetes</i> , 39(10): 1218-1227 (1990) (Abstract).
ll	Sreenan et al., "Prevention of Hyperglycemia in the Zucker Diabetic Fatty Rat by Treatment with Metformin or Troglitazone". <i>Am. J. Physiol.</i> , 271 (4 Pt 1): E742-E747 (1996) (Abstract).
EXAMINER	DATE CONSIDERED
llc llo	10-31-04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\kls\cases\p31902c3\PTO 1449 transferred refs form.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31902C3	SERIAL NO. Not Yet Assigned
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Buckingham et al.	
		FILING DATE Herewith	GROUP Not Yet Assigned

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>he</i>	5,708,012	1/13/98	Jerrold M. Olefsky	514	337	

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER <i>18-0000000</i>	DATE CONSIDERED 10-31-04
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	